# US 2023/0390205 A1 · Minimizing agglomeration of drug particle coating material during storage to stabilize disintegration times of pharmaceutical products

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0390205 A1
- Document ID: US20230390205A1
- Status: Published application
- Kind: A1
- Application number: 18/451,593
- Filed: 2023-08-17
- Published: 2023-12-07
- Earliest claimed: 2019-02-22
- Assignees: Catalent U.K. Swindon Zydis Limited
- Applicants: Catalent U.K. Swindon Zydis Limited
- Inventors: Rosaleen MCLAUGHLIN; Simon Andrew Martyn HOWES; Craig WHEADON; Jonathon WHITEHOUSE
- Web page: https://patentgrep.com/patent/US20230390205A1

## CPC

- A61K 9/167: {with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface (with further drug-free outer coating A61K9/5073)}
- A61K 9/5063: {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/5015)}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/1658: {Proteins, e.g. albumin, gelatin}
- A61K 9/2095: {Tabletting processes}
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions using solventless mixing methods. Excess coating material that is not bound to a coated API particle may be removed by a sieving process. Coating and dosing ratios can also be optimized to minimize the amount of excess unbound coating material. Specifically, a coating ratio and/or a dosing ratio can be used to minimize the residual amount of excess unbound coating material to minimize agglomeration of coating material during storage. In some embodiments, a pharmaceutical composition is provided, the pharmaceutical composition comprising: 65-85% w/w API particles; 15-30% w/w coating material coating the API particles; and 3-15% w/w matrix surrounding the coated API particles, wherein the pharmaceutical composition comprises a disintegration time rate of less than 10 seconds for at least six months under storage conditions of at least 25° C. and at least 60% relative humidity.

## Claims

### Claim 1

A pharmaceutical composition comprising:
65-85% w/w API particles;
15-30% w/w coating material encapsulating the API particles; and
3-15% w/w matrix surrounding the coated API particles, wherein the pharmaceutical composition comprises a disintegration time of less than 10 seconds for at least six months under storage conditions of at least 25° C. and at least 60% relative humidity.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises a disintegration time of less than 10 seconds for at least six months under storage conditions of at least 30° C. and at least 65% relative humidity.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises a disintegration time of less than 10 seconds for at least six months under storage conditions of at least 40° C. and at least 75% relative humidity.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the API particles comprise one or more of anti-inflammatories, analgesics, anti-psychotics, anti-emetics, laxatives, anti-diarrheals, anti-histamines, or anti-depressants.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the coating material comprises silica as one or more of a protective coating or a flow aid.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the coating material comprises a wax.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein the coating material comprises one or more of carnauba wax, candelilla wax, or synthetic wax.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, wherein a coating ratio used to combine the API particles with the coating material comprises 5-85% w/w coating material and 15-95% w/w uncoated API particles.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1, wherein the matrix comprises a matrix former and a structure former.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, wherein the matrix former comprises one or more of a water soluble material, a water dispersible material, a polypeptide, a polysaccharide, polyvinyl alcohol, polyvinylpyrrolidone, and acacia.

### Claim 11 (depends on 9)

The pharmaceutical composition of claim 9, wherein the matrix former comprises a polypeptide.

### Claim 12 (depends on 10)

The pharmaceutical composition of claim 10, wherein the polypeptide comprises gelatin.

### Claim 13 (depends on 8)

The pharmaceutical composition of claim 8, wherein the structure former comprises one or more of mannitol, dextrose, lactose, galactose, and cyclodextrin.

### Claim 14 (depends on 8)

The pharmaceutical composition of claim 8, wherein the structure former comprises mannitol.
